Clinical Report: Implantation of XEN‑45 for Treatment of Refractory Secondary Glaucoma
Overview
This study evaluates the efficacy of the XEN-45 gel stent in managing refractory secondary glaucoma (SG) in a Chinese patient population. Results indicate significant intraocular pressure (IOP) reduction and highlight the stent's potential as a viable surgical option when conventional treatments fail.
Background
Glaucoma is a major cause of irreversible vision loss, with secondary glaucoma (SG) being particularly challenging to manage due to its diverse etiologies. Traditional surgical interventions often carry substantial risks, prompting the need for safer alternatives. The XEN-45 gel stent represents a minimally invasive option that may improve outcomes for patients with refractory SG.
Data Highlights
No numerical data available in the provided material.
Key Findings
XEN-45 gel stents are effective in managing various forms of refractory secondary glaucoma.
The study included patients with diverse etiologies such as uveitic, steroid-induced, and traumatic glaucoma.
Minimally invasive techniques like ab externo implantation have gained popularity due to reduced intraocular manipulation.
Significant IOP reduction was observed in patients who underwent XEN-45 implantation.
Proactive management of blebs is crucial for optimizing surgical outcomes.
Clinical Implications
The XEN-45 gel stent offers a promising alternative for patients with refractory secondary glaucoma who do not respond to medical therapy or previous surgeries. Clinicians should consider this option while being mindful of the need for ongoing bleb management.
Conclusion
The implantation of XEN-45 gel stents demonstrates significant potential in treating refractory secondary glaucoma, warranting further investigation and consideration in clinical practice.
A panel of women in glaucoma shared personal experiences that have guided their approaches to surgical innovation, patient care, and mentorship, offering lessons that can inspire colleagues at every stage of their careers.
The movement of immune cells through the retinal vasculature has long been inferred from laboratory models. Now, advances in imaging are allowing clinicians to observe these processes directly. At the 2026 meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Denver, Richard B. Rosen, MD, ScD(hon), FACS, FASRS, FARVO, described early clinical work using adaptive optics scanning laser ophthalmoscopy (AOSLO) to visualize leukocyte trafficking in vivo.
FOXC1 duplications were the second most common monogenic finding among genetically solved juvenile open-angle glaucoma cases in one registry, supporting the use of copy-number variant analysis in early-onset glaucoma testing.
